JP2022527482A5 - - Google Patents
Info
- Publication number
- JP2022527482A5 JP2022527482A5 JP2021557790A JP2021557790A JP2022527482A5 JP 2022527482 A5 JP2022527482 A5 JP 2022527482A5 JP 2021557790 A JP2021557790 A JP 2021557790A JP 2021557790 A JP2021557790 A JP 2021557790A JP 2022527482 A5 JP2022527482 A5 JP 2022527482A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- erdafitinib
- dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025230741A JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19166429 | 2019-03-29 | ||
| EP19166429.1 | 2019-03-29 | ||
| US201962833395P | 2019-04-12 | 2019-04-12 | |
| US62/833,395 | 2019-04-12 | ||
| PCT/EP2020/058814 WO2020201138A1 (en) | 2019-03-29 | 2020-03-27 | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025230741A Division JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527482A JP2022527482A (ja) | 2022-06-02 |
| JP2022527482A5 true JP2022527482A5 (cg-RX-API-DMAC7.html) | 2024-07-24 |
Family
ID=69954076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557790A Pending JP2022527482A (ja) | 2019-03-29 | 2020-03-27 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
| JP2025230741A Pending JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025230741A Pending JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
Country Status (15)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021011926A (es) | 2019-03-29 | 2021-11-03 | Janssen Pharmaceutica Nv | Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. |
| US20230321087A1 (en) * | 2020-09-14 | 2023-10-12 | Janssen Pharmaceutica Nv | Fgfr inhibitor combination therapies |
| WO2022243467A1 (en) * | 2021-05-19 | 2022-11-24 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors |
| AU2022289906A1 (en) * | 2021-06-07 | 2023-11-09 | R.P. Scherer Technologies, Llc | Protective coating for moisture sensitive pharmaceutical compositions |
| IL312063A (en) | 2021-10-12 | 2024-06-01 | Taris Biomedical Llc | Ardafitinib formulations and systems for intravesical administration |
| WO2023159216A1 (en) | 2022-02-18 | 2023-08-24 | Taris Biomedical Llc | Erdafitinib formulations and osmotic systems for intravesical administration |
| CN116106240B (zh) * | 2022-12-26 | 2025-11-07 | 华中农业大学 | 一种尿液酪氨酸检测体系、检测方法及检测试剂盒 |
| IL322667A (en) | 2023-02-13 | 2025-10-01 | Taris Biomedical Llc | Ardepitinib for intravesical administration for use in the treatment of bladder cancer |
| CN120731077A (zh) | 2023-02-17 | 2025-09-30 | 塔里斯生物医药公司 | 膀胱内施用厄达替尼以用于治疗膀胱癌 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| SG11201702381QA (en) | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| CA3049737A1 (en) * | 2017-02-06 | 2018-08-09 | Janssen Pharmaceutica Nv | Cancer treatment |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2020
- 2020-03-27 US US17/598,985 patent/US20220175768A1/en active Pending
- 2020-03-27 CA CA3130773A patent/CA3130773A1/en active Pending
- 2020-03-27 PH PH1/2021/552352A patent/PH12021552352A1/en unknown
- 2020-03-27 MA MA055486A patent/MA55486A/fr unknown
- 2020-03-27 CN CN202080026737.4A patent/CN113645975A/zh active Pending
- 2020-03-27 AU AU2020253054A patent/AU2020253054B2/en active Active
- 2020-03-27 EP EP20713656.5A patent/EP3946340A1/en active Pending
- 2020-03-27 WO PCT/EP2020/058814 patent/WO2020201138A1/en not_active Ceased
- 2020-03-27 MX MX2021011943A patent/MX2021011943A/es unknown
- 2020-03-27 KR KR1020217034729A patent/KR20210143878A/ko not_active Ceased
- 2020-03-27 EP EP24174999.3A patent/EP4548935A3/en active Pending
- 2020-03-27 JP JP2021557790A patent/JP2022527482A/ja active Pending
- 2020-03-27 SG SG11202109854R patent/SG11202109854RA/en unknown
- 2020-03-27 BR BR112021019203A patent/BR112021019203A2/pt unknown
-
2021
- 2021-09-23 JO JOP/2021/0260A patent/JOP20210260A1/ar unknown
- 2021-09-26 IL IL286727A patent/IL286727A/en unknown
-
2025
- 2025-12-04 JP JP2025230741A patent/JP2026048748A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4337191B1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| Takahashi et al. | High-dose intravenous vitamin C improves quality of life in cancer patients | |
| Sanchez-Lopez et al. | Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling | |
| CN109310754A (zh) | 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法 | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| Kanda et al. | Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy | |
| JP2025038167A (ja) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 | |
| Adhikaree et al. | Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy | |
| JP2023513298A5 (cg-RX-API-DMAC7.html) | ||
| Alexandraki et al. | Medical therapy for craniopharyngiomas | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| JP2022527189A5 (cg-RX-API-DMAC7.html) | ||
| Shihab et al. | Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| Fujimoto et al. | Successful treatment with ramucirumab plus erlotinib following osimertinib-induced interstitial lung disease | |
| TW202237100A (zh) | 使用包含gdc-9545及gdc-0077之組合療法治療乳癌 | |
| US20220348662A1 (en) | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings | |
| Calvo et al. | Management of mTOR inhibitors oral mucositis: current state of knowledge | |
| Hashmi et al. | The effects of voriconazole on metabolism of all-trans retinoic acid in the treatment of acute promyelocytic leukemia: a case report | |
| KR20230132496A (ko) | 고정 용량의 타미바로텐을 사용하는 치료 용법 | |
| de Bono et al. | Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC) | |
| KR102895850B1 (ko) | Isa-2011b와 엘로티닙을 포함하는 암 예방 또는 치료를 위한 병용 투여용 약학적 조성물 | |
| Chiba et al. | Deterioration of glycemic control contributes to the prevalence of proteinuria among bevacizumab-treated cancer patients with type 2 diabetes mellitus | |
| EP4452275B1 (en) | Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers |